Abstract
Immunotherapy has demonstrated efficacy in non-small cell lung cancer (NSCLC) in the first-line setting as well as in further lines. Use of standardized flat dose became a standard. Pharmacological studies allow us an extended interval dosing of immunotherapy. It was particularly useful in the period of pandemic. Duration of immunotherapy is still on debate, taking into account constraints related to long term efficacy, toxicity and cost. Administrating cancer ICIs in hospital-at-home setting is feasible. This review develop these points.1877-1203/© 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
